Message #4 From:
Stock News Bot Date: December 1, 2006 11:16:00 AM
BGES News Bio-Bridge Science Dedicated to Developing a Vaccine to Fight HIV
OAK-BROOK,-Ill.--(BUSINESS WIRE)--According to a joint report issued by UNAIDS and WHO, an estimated 39.5
million people globally are living with HIV and an estimated 4.3 million
individuals were newly infected during 2006. An overwhelming proportion
of the people living with HIV are in Sub-Saharan Africa where the
estimated number of people infected is 24.7 million. The number of
people estimated to be living with HIV is 1.2 million in the U.S.,
650,000 in China, and 17,000 in Japan. China's Ministry of Health
expressed recently that the number of people officially reported as
infected by HIV has risen 27.5 percent since the beginning of 2006
according to Xinhua. To curb the global spread of HIV, experts believe
that a vaccine is needed to fight HIV infection.
Bio-Bridge Science, Inc. (OTCBB: BGES) is in development of a promising
new HIV Vaccine that is expected to enter clinical trials in 2007 in
China. The vaccine targets infection in mucosal tissues, which is a
unique approach to prevent and treat HIV infection. The pre-clinical
trials have been done in China and suggest that the vaccine is safe and
effective in the treatment and prevention of HIV. Bio-Bridge is
dedicated to developing this HIV therapeutic and preventive vaccine to
fight HIV/AIDS.
This press release contains forward-looking statements as defined by the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements include statements concerning plans, objectives, goals,
strategies, future events or performance, and underlying assumptions and
other statements that are other than statements of historical facts.
These statements are subject to uncertainties and risks including, but
not limited to, product and service demand and acceptance, changes in
technology, economic conditions, the impact of competition and pricing,
government regulation, and other risks defined in this document and in
statements filed from time to time with the Securities and Exchange
Commission. All such forward-looking statements, whether written or
oral, and whether made by or on behalf of the company, are expressly
qualified by these cautionary statements and any other cautionary
statements which may accompany the forward-looking statements. In
addition, the company disclaims any obligation to update any
forward-looking statements to reflect events or circumstances after the
date hereof. Please refer to SEC filings for additional information.
